ASCO/ESMO 2020 PembroRAD Trial Update

dbrock's picture
Outcome of the PembroRAD Trial: Pembrolizumab (Keytruda) or Cetuximab (Erbitux) Combined with Radiation Therapy in Patients with Locally Advanced HNSCC
Joshua Bauml, MD, GRACE Faculty, Advisory Board
We are pleased to present this newest video series of updates from ASCO and ESMO 2020, with discussions on updates to head and neck cancer treatments and trials.

Dr. Joshua Bauml, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and Dr. Jared Weiss, Associate Professor of Medicine at UNC Chapel Hill and Vice President of the Board of GRACE chaired this program highlighting updates for those dealing with a diagnosis of locally advanced HNSCC. Drs. Bauml and Weiss spoke with Dr. Kathryn Gold, Medical Oncologist and Associate Professor of Medicine at the University of California San Diego and Dr. Ranee Mehra, Professor of Medical Oncology at the University of Maryland, on the newest updates to 2020 trials and studies presented at ASCO and ESMO this year.

For this discussion, Drs. Bauml, Weiss, Gold and Mehra discuss the outcome of the PembroRAD Trial: Pembrolizumab (Keytruda) or Cetuximab (Erbitux) combined with radiation therapy in patients with locally advanced HNSCC.


To join the conversation, visit

Video Language: 


Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation